Clinical Studies

Call the Mercy Medical Research Institute at (417)841-0250 or toll-free 1-866-207-0167 (for those outside the 417 area code) if you are interested in participating in a clinical trial. You may also want to contact your physician for more information before participating.

Z11102

Impact of breast conservation surgery on surgical outcomes and cosmesis in patients with multiple ipsilateral breast cancers (MIBC)

Investigators:
Alan Hollingsworth, M.D.

S1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Investigators:
Vicki Canfield, M.D.

S1007

Phase III Randomized, Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.

Investigators:
Vicki Canfield, M.D.

S0931

EVEREST: EVErolimus for renal cancer enduring surgical therapy, a phase III study

Investigators:
Vicki Canfield, M.D.

NRG-HN002

A randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer

Investigators:
Astrid Morrison, M.D.

NRG-BR003

A randomized phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node negative triple-negative invasive breast cancer

Investigators:
Vicki Canfield, M.D.

NASBP B-51

A randomized phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy

Investigators:
Astrid Morrison, M.D.

ML 28257

An observational cohort study of treatment patterns and outcomes in patients with HER 2 Positive (HER2+) metastatic breast cancer

Investigators:
Vicki Canfield, M.D.

MHE104317

A compassionate use open-label study of anti IL-5 (Mepolizumab) treatment in subjects with hypereosinophilic syndrome

Investigators:
Jess Armor, M.D.

EMR 100070-004

A phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based as a first-line treatment of recurrent or stage IV PD-L1 + non-small cell lung cancer

Investigators:
James Reeves, M.D.

E4512

A Phase II Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (A companion protocol to ALCHEMIST A151216)

Investigators:
Suzanne Cole, M.D.

E3612

A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma

Investigators:
Vicki Canfield, M.D.

E2810

Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have no Evidence of Disease Following Metastatectomy

Investigators:
Vicki Canfield, M.D.

CP-MGAH22-04

A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2 + Metastatic breast cancer who have received two prior anti-HER2 therapies and require systemic treatment

Investigators:
Suzanne Cole, M.D.

CLEE011F2301 MONALEESA-3

MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of post menopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no prior endocrine treatment or only one line of prior endocrine treatment

Investigators:
James Reeves, M.D.

CDX-011-04

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer

Investigators:
Vicki Canfield, M.D.

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer

Investigators:
Vicki Canfield, M.D.

B1771007

A Randomized Phase 4 Study comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects with Relapsed, Refractory Mantle Cell Lymphoma

Investigators:
Vicki Canfield, M.D.

A151216 (The ALCHEMIST Screening Trial)

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Investigators:
Suzanne Cole, M.D.

A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Investigators:
Suzanne Cole, M.D.

A031201

Phase III trial of enzalutamide versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer

Investigators:
Vicki Canfield, M.D.

Enterra II Therapy System for Gastric Electrical Stimulaiton

HDE Number H99014/S807

Investigators:
Kenneth Watts, M.D.

Breast Cancer Collaborative Registry

BCCR

Investigators:
Samir Dalia, M.D.

LTFU Administrative Tool for SWOG Protocols

S9808

Investigators:
Tony Flippin M.D.

SWOG Southwest Oncology Group

S1403

Investigators:
Tony Flippin M.D.

Biospecimen Bank for PACCT1

PACCT1/EL112LAB

Investigators:
Tony Flippin M.D.

Breast CA Rx based on BRAC gene evaluation

NSABP-B55/BIG6-13

Investigators:
Tony Flippin M.D.

Multiple Myeloma Registry

Connect MM

Investigators:
Tony Flippin M.D.